Page last updated: 2024-12-07

clitocine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

clitocine: structure & RN given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	129111
CHEMBL ID	304179
CHEBI ID	178144
SCHEMBL ID	182039
MeSH ID	M0156060

Synonyms (25)

Synonym
105798-74-1
(2r,3r,4s,5r)-2-[(6-amino-5-nitropyrimidin-4-yl)amino]-5-(hydroxymethyl)oxolane-3,4-diol
CHEBI:178144
clitocine
CHEMBL304179 ,
(2r,3r,4s,5r)-2-(6-amino-5-nitro-pyrimidin-4-ylamino)-5-hydroxymethyl-tetrahydro-furan-3,4-diol
2-(6-amino-5-nitro-pyrimidin-4-ylamino)-5-hydroxymethyl-tetrahydro-furan-3,4-diol
bdbm50100587
6-amino-5-nitro-4-(ribofuranosylamino)pyrimidine
unii-9z4qxq98qw
9z4qxq98qw ,
beta-d-ribofuranosylamine, n-(6-amino-5-nitro-4-pyrimidinyl)-
(2r,3r,4s,5r)-2-(6-amino-5-nitropyrimidin-4-ylamino)-5-(hydroxymethyl)-tetrahydrofuran-3,4-diol
SCHEMBL182039
6-amino-5-nitro-4-(beta-d-ribo-furanosylamino) pyrimidine
n-(6-amino-5-nitro-4-pyrimidinyl)-beta-d-ribofuranosylamine
HY-118341
Q16949273
CS-0065721
F82267
MS-24099
DTXSID30909739
STARBLD0000883
AKOS040751216
PD157030

Research Excerpts

Overview

Clitocine is a natural amino nucleoside isolated from mushroom. It has been shown to inhibit cancer cell proliferation in vitro.

Excerpt	Reference	Relevance
"Clitocine is a natural amino nucleoside isolated from mushroom and has been shown to inhibit cancer cell proliferation in vitro."	( Clitocine targets Mcl-1 to induce drug-resistant human cancer cell apoptosis in vitro and tumor growth inhibition in vivo. Fung, KP; Li, H; Li, X; Liu, FY; Sun, JG; Wu, P; Zeng, X, 2014)	2.57

Treatment

Excerpt	Reference	Relevance
"Clitocine treatment inhibited drug-resistant human cancer cell growth in vitro in a dose- and time-dependent manner."	( Clitocine targets Mcl-1 to induce drug-resistant human cancer cell apoptosis in vitro and tumor growth inhibition in vivo. Fung, KP; Li, H; Li, X; Liu, FY; Sun, JG; Wu, P; Zeng, X, 2014)	2.57

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
N-glycosyl compound	A glycosyl compound arising formally from the elimination of water from a glycosidic hydroxy group and an H atom bound to a nitrogen atom, thus creating a C-N bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Adenosine kinase	Homo sapiens (human)	IC50 (µMol)	26.0000	0.0005	0.6052	10.0000	AID91548
Adenosine kinase	Homo sapiens (human)	Ki	1.9333	0.0163	0.7415	3.0000	AID33991; AID33992; AID33994
Adenosine kinase	Rattus norvegicus (Norway rat)	IC50 (µMol)	2.0000	0.0017	0.5834	2.0000	AID33996; AID33997
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (7)

Process	via Protein(s)	Taxonomy
purine ribonucleoside salvage	Adenosine kinase	Homo sapiens (human)
dATP biosynthetic process	Adenosine kinase	Homo sapiens (human)
ribonucleoside monophosphate biosynthetic process	Adenosine kinase	Homo sapiens (human)
GMP salvage	Adenosine kinase	Homo sapiens (human)
AMP salvage	Adenosine kinase	Homo sapiens (human)
dAMP salvage	Adenosine kinase	Homo sapiens (human)
purine nucleobase metabolic process	Adenosine kinase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Process	via Protein(s)	Taxonomy
RNA binding	Adenosine kinase	Homo sapiens (human)
deoxyadenosine kinase activity	Adenosine kinase	Homo sapiens (human)
ATP binding	Adenosine kinase	Homo sapiens (human)
metal ion binding	Adenosine kinase	Homo sapiens (human)
adenosine kinase activity	Adenosine kinase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Process	via Protein(s)	Taxonomy
nucleoplasm	Adenosine kinase	Homo sapiens (human)
cytosol	Adenosine kinase	Homo sapiens (human)
plasma membrane	Adenosine kinase	Homo sapiens (human)
nucleus	Adenosine kinase	Homo sapiens (human)
cytosol	Adenosine kinase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (8)

Assay ID	Title	Year	Journal	Article
AID33994	Inhibition of rabbit liver adenosine kinase	1988	Journal of medicinal chemistry, Apr, Volume: 31, Issue:4	Synthesis, intramolecular hydrogen bonding, and biochemical studies of clitocine, a naturally occurring exocyclic amino nucleoside.
AID33991	Binding affinity towards adenosine kinase	1988	Journal of medicinal chemistry, Apr, Volume: 31, Issue:4	Synthesis, intramolecular hydrogen bonding, and biochemical studies of clitocine, a naturally occurring exocyclic amino nucleoside.
AID217934	Inhibition of growth of human B lymphoblast derived W1-L2 cells	1988	Journal of medicinal chemistry, Apr, Volume: 31, Issue:4	Synthesis, intramolecular hydrogen bonding, and biochemical studies of clitocine, a naturally occurring exocyclic amino nucleoside.
AID98697	In vitro inhibition of L1210 cells	1988	Journal of medicinal chemistry, Apr, Volume: 31, Issue:4	Synthesis, intramolecular hydrogen bonding, and biochemical studies of clitocine, a naturally occurring exocyclic amino nucleoside.
AID91548	Inhibition of adenosine phosphorylation in confluent IMR-32 (human neuroblastoma) cells.	2001	Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13	Discovery of 4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine, an orally active, non-nucleoside adenosine kinase inhibitor..
AID33992	Inhibition of adenosine kinase from undialyzed W1-L2 lysate (0-50 uM)	1988	Journal of medicinal chemistry, Apr, Volume: 31, Issue:4	Synthesis, intramolecular hydrogen bonding, and biochemical studies of clitocine, a naturally occurring exocyclic amino nucleoside.
AID33996	In vitro inhibition of Adenosine kinase (AK)	2001	Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13	Discovery of 4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine, an orally active, non-nucleoside adenosine kinase inhibitor..
AID33997	In vitro inhibition of Adenosine kinase of rat brain cytosol.	2001	Bioorganic & medicinal chemistry letters, Sep-17, Volume: 11, Issue:18	Synthesis and biological evaluation of clitocine analogues as adenosine kinase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (8.33)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (41.67)	29.6817
2010's	6 (50.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.73

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	21.73 (24.57)
Research Supply Index	2.56 (2.92)
Research Growth Index	5.00 (4.65)
Search Engine Demand Index	18.60 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (21.73)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (8.33%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	11 (91.67%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
abt 702 [no description available]	2	1	bipyridines
5'-amino-5'-deoxyadenosine [no description available]	2.41	2
abt-737 [no description available]	7.1	1	aromatic amine; aryl sulfide; biphenyls; C-nitro compound; monochlorobenzenes; N-arylpiperazine; N-sulfonylcarboxamide; secondary amino compound; tertiary amino compound	anti-allergic agent; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
adenosine kinase Adenosine Kinase: An enzyme that catalyzes the formation of ADP plus AMP from adenosine plus ATP. It can serve as a salvage mechanism for returning adenosine to nucleic acids. EC 2.7.1.20.	7.39	2
nitrophenols Nitrophenols: PHENOLS carrying nitro group substituents.	2.1	1
acyclovir Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.	2	1	2-aminopurines; oxopurine	antimetabolite; antiviral drug

Condition	Relationship Strength	Studies
Leukemia L 1210 [description not available]	1.97	1
Chronic Illness [description not available]	3.06	1
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted [description not available]	3.06	1
Cirrhosis, Liver [description not available]	3.06	1
Cancer of Liver [description not available]	3.06	1
Acute Disease Disease having a short and relatively severe course.	3.06	1
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	3.06	1
Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.	3.06	1
Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.	3.06	1
Liver Neoplasms Tumors or cancer of the LIVER.	3.06	1
Cancer of Colon [description not available]	2.52	2
Colonic Neoplasms Tumors or cancer of the COLON.	2.52	2
Cancer of Ovary [description not available]	2.15	1
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	2.15	1
Cancer of Cervix [description not available]	2.04	1
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	2.04	1
Cytomegalovirus A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.	2	1

chemdatabank.com